Bio­gen vet George Scan­gos jumps on the board at up­start MS case man­ag­er Oc­tave, backed by Sec­tion 32

Some promi­nent biotech ex­ecs are step­ping up to sup­port the launch of a com­pa­ny called Oc­tave Bio­science, which has been build­ing a plat­form to guide the treat­ment of pa­tients with mul­ti­ple scle­ro­sis. 

Ex-Bio­gen CEO and cur­rent Vir chief George Scan­gos is tak­ing a board po­si­tion, along­side Sec­tion 32 man­ag­ing part­ner Michael Pelli­ni, who is back­ing the com­pa­ny’s $14 mil­lion A round.

Scan­gos helped change the stan­dard of care in MS with the launch of Tec­fidera at Bio­gen 5 years ago. But in MS, pa­tients have to be con­stant­ly mon­i­tored to see if they’re get­ting the best care, switch­ing drugs as need­ed. That’s where Oc­tave pro­pos­es to step in, us­ing the lat­est di­ag­nos­tic tools to stay on top of each case.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER